CN Mobile Logo

Search form


Gynecologic Cancers

Gynecologic Cancers

In this interview we discuss a recent study that found that more than half of patients with locally advanced cervical cancer in the United States did not receiving standard of care.

The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.

The use of surveillance did not affect survival among women with stage I malignant ovarian germ cell tumors, according to a new retrospective analysis.

Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.

A new paper highlights the global inequities in access to prevention, early detection and treatment for breast cancer and cervical cancer.


Subscribe to Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.